Business · Companies · 1 hr ago
OpenAI acquires AI platform company Orchestra Bio
OpenAI has acquired Orchestra Bio, a company whose AI platform is used in drug development.
The platform coordinates and manages drug-development processes.
OpenAI plans to combine it with Rosalind, its AI tools project for life-sciences research.
The acquisition is part of OpenAI's effort to speed up new-drug development.
OpenAI announced the deal on Oct 20, local time.
The company has said it plans to combine the platforms, but gave no further details on what happens next.
OpenAI acquired Orchestra Bio, an AI software startup serving the biotech industry.
OpenAI said it plans to add Orchestra Bio’s team and technology to its Rosalind life sciences research project.
Orchestra Bio makes AI agents that help biotech companies manage drug discovery operations, including finances and clinical-trial scheduling.
The terms of the acquisition were not disclosed.
Orchestra Bio had reportedly raised around $20 million by 2025.
- Who
- OpenAI acquired Orchestra Bio, a biotech software startup.
- What
- OpenAI acquired the company and plans to add its team and technology to Rosalind.
- When
- OpenAI announced the acquisition on October 20, 2026.
- Where
- Not stated
- Why
- OpenAI said Orchestra Bio’s team and technology would work on Rosalind and its related Workbench tool for life sciences research.
This story does not have two clearly opposing sides.
Orchestra Bio had reportedly raised around $20 million by this year.
OpenAI announced that it had acquired Orchestra Bio.
- Acquirer
- OpenAI
- Company acquired
- Orchestra Bio
- Announcement date
- October 20, 2026
- Reported funding
- Around $20 million by 2025
- OpenAI life sciences project
- Rosalind